Press Releases

World Cancer Day: Celleron Therapeutics Commitment to Pioneering Therapies for Cancers

Feb 4, 2019

Oxford, UK, February 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, on World Cancer Day

Celleron Therapeutics announces successful completion of Phase 1b Clinical Trial

Jan 14, 2019

Celleron Therapeutics Successfully Completes Safety Evaluation of Pioneering Combination Therapy Approach to Treating Colorectal Cancer Oxford, UK, 14th January 2019

Celleron Therapeutics Announces the appointment of Simon Cook as Clinical Research Director

Jan 14, 2019

Celleron Therapeutics appoints Simon Cook as its Clinical Research Director Oxford 14 January 2019; Celleron Therapeutics Limited, the UK based

2018 Professor David Kerr Presents at the 3rd, World Precision Medicine (China) Summit in Shanghai.

Dec 20, 2018

Oxford 20th December 2018 – Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics,

Dr Shunsheng Zheng appointed as Business Development Director

Nov 12, 2018

November 12th 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today

Dr Hao Zhang appointed as Vice President Business Development and Commercialisation

Oct 18, 2018

Oxford 1st October 2018;Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today

2018 Shenzhen Pingshan International Biopharmaceutical Industry Innovation & Development Summit

Oct 1, 2018

Oxford 21 September 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Celleron Therapeutics Begins a Pioneering Combination Therapy Approach to Treating Colorectal Cancer

Aug 20, 2018

Oxford, UK, 20th August 2018 – Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced the

Celleron Therapeutics announces Initiation of Patient Enrolment into the Expansion Cohort of its CXD101 Phase 1 Clinical Trial

Jun 11, 2018

The expansion cohort of our Phase I clinical trial is open to patient enrolment.

Celleron Therapeutics Selects Syneos Health to Conduct Clinical Trial Programme for CXD101 on MAY 1, 2018

May 1, 2018

The company has selected Syneos Health, a leading biopharmaceutical solutions organization, to conduct clinical trials for its lead compound CXD101 in colorectal cancer.